2021
DOI: 10.1111/ceo.13979
|View full text |Cite
|
Sign up to set email alerts
|

Selective laser trabeculoplasty: A review

Abstract: Glaucoma is the second most prevalent cause of blindness worldwide, and the only effective management is the lowering of intraocular pressure (IOP). Selective laser trabeculoplasty (SLT) has become an essential part of glaucoma management since its commercial release in 2001. It has been an improvement from the previous argon laser trabeculoplasty (ALT), by using 1% of the laser energy, reducing the amount of anterior segment inflammation and minimising the degree of mechanical injury to the trabecular meshwor… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(2 citation statements)
references
References 83 publications
0
2
0
Order By: Relevance
“…The only factor reliably shown to be associated with SLT efficacy is pre‐SLT IOP. A higher IOP before SLT seems to be associated with a greater SLT response (Landers, 2021).…”
Section: Introductionmentioning
confidence: 99%
“…The only factor reliably shown to be associated with SLT efficacy is pre‐SLT IOP. A higher IOP before SLT seems to be associated with a greater SLT response (Landers, 2021).…”
Section: Introductionmentioning
confidence: 99%
“…Since 2000, the management of glaucoma has continued to expand beyond intraocular pressure lowering eye drops and filtering surgery to include selective laser trabeculoplasty and microinvasive glaucoma surgery, or SLT and MIGS, respectively. Landers 16 provided a comprehensive review of SLT, covering mechanism of action, technical aspects of the procedure, application in different subtypes of glaucoma, outcomes and complications, repeatability and cost effectiveness. Berdahl et al 17 reported the 4-year outcomes of a trabecular microbypass stent (iStent inject) implantation, combined with travoprost eye drops, in a prospective, non-randomised study involving 53 individuals with open-angle glaucoma.…”
mentioning
confidence: 99%